Ifosfamide-induced neurotoxicity: a case report and review of the literature

OBJECTIVE: To review published abstracts, journal articles, and case reports for evidence of ifosfamide-induced neurotoxicity in both adult and pediatric populations. DATA SOURCES: Peer-reviewed journal articles (October 1985 through August 1990) obtained through a computer literature search, with subsequent bibliography scanning. STUDY SELECTION: We identified 34 reports that specifically addressed neurotoxicity related to ifosfamide therapy. By consensus of the authors, 8 of these reports were excluded due to a small study population, duplication of age of data. DATA EXTRACTION: Studies were assessed by the first author and verified by the second author. Several colleagues also contributed to the analysis. DATA ANALYSIS: Risk factors and mechanisms behind this potentially fatal neurotoxic reaction remain speculative and, in some cases, contradictory. The predictive capability of a published nomogram is restricted by differences in dosage regimens and encephalopathic classifications. Currently, the best prevention against neurotoxicity is little or no use of concurrent medications that have central nervous system effects. CONCLUSIONS: Further studies should address the influence of other nephrotoxic agents (e.g., cisplatin, aminoglycosides) on the incidence of ifosfamide-induced neurotoxicity.

This article has been cited by other articles:

				J. Dietrich, J. Marienhagen, B. Schalke, U. Bogdahn, and F. Schlachetzki Vascular Neurotoxicity Following Chemotherapy with Cisplatin, Ifosfamide, and Etoposide Ann. Pharmacother., February 1, 2004; 38(2): 242 - 246. [Abstract] [Full Text] [PDF]

				S. Donegan Novel treatment for the management of ifosfamide neurotoxicity: Rationale for the use of methylene blue Journal of Oncology Pharmacy Practice, January 1, 2001; 6(4): 153 - 165. [Abstract] [PDF]